Miniature Heart Device And Wider Lingo Access Could Be A Game Changer For Abbott (ABT)

• Earlier this month, Abbott announced U.S. FDA clearance and CE Mark for its Amplatzer Piccolo Delivery System, enhancing minimally invasive treatment of patent ductus arteriosus in premature infants, while also expanding access to its Lingo over-the-counter continuous glucose monitor to Android users in the wellness market.
• Together, these moves underscore Abbott’s push to pair specialized pediatric cardiology devices with broader consumer-facing glucose insights, tightening the link between its medical technology portfolio and everyday health management.
• Next, we’ll explore how this expansion of Lingo’s glucose-monitoring ecosystem could reshape Abbott’s existing investment narrative.

The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

Abbott Laboratories Investment Narrative Recap

To own Abbott, you need to believe in its ability to compound value from a diversified healthcare portfolio while managing pricing and regulatory pressure in diagnostics and devices. The latest Piccolo and Lingo updates strengthen its medical and wellness ecosystems, but do not materially change the near term focus on protecting diabetes device economics and pricing power, where US CGM reimbursement and competition remain a key catalyst and a central risk.

Among recent announcements, the expansion of Lingo to Android stands out as most relevant, because it reinforces Abbott’s broader glucose technology franchise at a time when competitive bidding and rivals in CGM could pressure pricing. Extending access to non insulin users may help deepen Abbott’s data and brand presence in metabolic health, which sits alongside Libre in the core diabetes ecosystem that many investors already view as central to the story.

Yet even as the product story broadens, investors should be aware that pricing pressure in continuous glucose monitoring could...

Read the full narrative on Abbott Laboratories (it's free!)

Abbott Laboratories' narrative projects $53.3 billion revenue and $9.4 billion earnings by 2028. This implies 7.3% yearly revenue growth and an earnings decrease of $4.5 billion from $13.9 billion today.

Uncover how Abbott Laboratories' forecasts yield a $144.43 fair value, a 15% upside to its current price.

Exploring Other Perspectives

Eleven fair value estimates from the Simply Wall St Community span roughly US$73 to US$144 per share, showing how differently people assess Abbott’s potential. As you weigh those views, keep in mind that the same CGM pricing pressure that worries analysts also shapes the long term earnings path many community members are trying to model.

Explore 11 other fair value estimates on Abbott Laboratories - why the stock might be worth 41% less than the current price!

Build Your Own Abbott Laboratories Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Abbott Laboratories research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Abbott Laboratories research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Abbott Laboratories' overall financial health at a glance.

No Opportunity In Abbott Laboratories?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Explore 28 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• AI is about to change healthcare. These 29 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Rare earth metals are the new gold rush. Find out which 35 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com